IDEXX LABS INC shareholders Q3 2023

IDEXX LABS INC's ticker is IDXX and the CUSIP is 45168D104. A total of 1,040 filers reported holding IDEXX LABS INC in Q3 2023. The put-call ratio across all filers is 1.15 and the average weighting 0.3%.

IDEXX LABS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Pictet Asset Management Holding SA 361,900$158,248,0130.20%
Neuberger Berman Group LLC 487,846$213,320,2190.19%
GAM Holding AG 6,006$2,626,3220.19%
SpiderRock Advisors, LLC 5,000$2,2900.19%
MACQUARIE GROUP LTD 344,236$150,524,2100.19%
Wealth Quarterback LLC 500$218,6350.19%
MOSELEY INVESTMENT MANAGEMENT INC 725$317,0210.19%
Charter Oak Capital Management, LLC 3,252$1,422,0030.19%
Thematics Asset Management 8,748$3,825,2380.19%
IMS Capital Management 722$315,7090.19%
abrdn plc 167,964$73,445,6190.19%
Atlas Brown,Inc. 937$409,7220.19%
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC 149,486$65,365,7430.19%
Peregrine Asset Advisers, Inc. 818$357,6870.19%
Portland Global Advisors LLC 2,523$1,1030.18%
D.B. Root & Company, LLC 1,078$471,3770.18%
CIBC Private Wealth Group, LLC 176,394$77,131,8050.18%
AXA S.A. 119,015$52,041,6890.18%
Siemens Fonds Invest GmbH 4,138$1,809,4230.18%
Legacy Advisors, LLC 2,570$1,123,7840.18%
About IDEXX LABS INC

IDEXX Laboratories, Inc. is a leading provider of diagnostic and information technology solutions for animal health. The company offers a wide range of products and services to veterinarians, livestock producers, and pet owners worldwide. IDEXX's mission is to enhance the health and well-being of pets, people, and livestock.

IDEXX's core business is in veterinary diagnostics, which includes blood and urine tests, digital imaging, and other diagnostic services. The company's products are used to diagnose and manage a variety of animal diseases, including cancer, heart disease, and infectious diseases.

IDEXX has a strong reputation for innovation and has been recognized for its contributions to the animal health industry. The company has received numerous awards for its products and services, including the Frost & Sullivan Company of the Year Award for Animal Health Diagnostics.

IDEXX has a strong financial position, with a market capitalization of over $30 billion. The company has consistently delivered strong financial results, with revenue growth of over 10% in the most recent quarter.

In conclusion, IDEXX Laboratories, Inc. is a leading provider of diagnostic and information technology solutions for animal health. The company has a strong reputation for innovation and has been recognized for its contributions to the animal health industry. With a strong financial position and consistent revenue growth, IDEXX is well-positioned for continued success in the future.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists IDEXX LABS INC's shareholders in Q3 2023. To view IDEXX LABS INC's shareholder history, click here.